Executive leader for North American regulatory affairs for Eli Lilly and Company. The organization is responsible for all US and Canadian human drugs and devices regulatory affairs, and global manufacturing regulatory affairs. Organization provides strategic and operational regulatory capabilities required for defining the strategy and requirements for support of clinical development, product development and marketed drug and device products across the company. Additionally, the organization leads external regulatory policy that shapes the US environment for innovative drug development. Provides leadership to Lilly governance committees, including chairing the Medical Research Committee, to ensure project and portfolio strategies meet business needs and are effectively executed.

Serves on the board of directors for the Lilly PAC, and represents Lilly at the Pharmaceutical Manufacturers of America Scientific and Regulatory Advisory Committee and the National Academies of Sciences Forum on Drug Discovery, Development and Translation. Invited lecturer at the Indiana University School of Medicine and Purdue University. Director of the NIH NCATS & Lilly Scholars Program